{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,6]],"date-time":"2022-04-06T02:37:19Z","timestamp":1649212639163},"reference-count":89,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,7]]},"DOI":"10.1097\/jcn.0b013e31821bf93f","type":"journal-article","created":{"date-parts":[[2013,7,4]],"date-time":"2013-07-04T01:54:31Z","timestamp":1372902871000},"page":"303-316","source":"Crossref","is-referenced-by-count":0,"title":["Niacin\u2014A Critical Component to the Management of Atherosclerosis"],"prefix":"10.1097","volume":"27","author":[{"given":"Carol M.","family":"Mason","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy L.","family":"Doneen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"issue":"5","key":"R2-5-20210128","doi-asserted-by":"crossref","first-page":"e69","DOI":"10.1161\/CIRCULATIONAHA.106.179918","article-title":"Heart disease and stroke statistics2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee.","volume":"115","author":"Rosamond","year":"2007","journal-title":"Circulation"},{"issue":"12","key":"R3-5-20210128","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1161\/CIRCULATIONAHA.106.658948","article-title":"Increasing cardiovascular disease burden due to diabetes mellitus: the Framingham Heart Study.","volume":"115","author":"Fox","year":"2007","journal-title":"Circulation"},{"issue":"7","key":"R4-5-20210128","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.2337\/diacare.21.7.1138","article-title":"Mortality in adults with and without diabetes in a national cohort of the U.S. population, 1971-1993.","volume":"21","author":"Gu","year":"1998","journal-title":"Diabetes Care"},{"issue":"15","key":"R5-5-20210128","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1016\/j.jacc.2008.02.034","article-title":"Lipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation.","volume":"51","author":"Brunzell","year":"2008","journal-title":"J Am Coll Cardiol"},{"issue":"25","key":"R6-5-20210128","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1161\/circ.106.25.3143","article-title":"Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report.","volume":"106","year":"2002","journal-title":"Circulation"},{"issue":"5","key":"R7-5-20210128","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/HCO.0b013e32832ebfe7","article-title":"Enhancing cardiovascular disease risk reduction: raising high-density lipoprotein levels.","volume":"24","author":"Hausenloy","year":"2009","journal-title":"Curr Opin Cardiol"},{"issue":"4","key":"R8-5-20210128","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.amjcard.2009.04.008","article-title":"Plasma triglycerides and cardiovascular events in the Treating to New Targets and incremental decrease in end-points through aggressive lipid lowering trials of statins in patients with coronary artery disease.","volume":"104","author":"Faergeman","year":"2009","journal-title":"Am J Cardiol"},{"issue":"1","key":"R9-5-20210128","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ahj.2008.08.010","article-title":"Lipid levels in patients hospitalized with coronary artery disease: an analysis of 136,905 hospitalizations in Get With the Guidelines.","volume":"157","author":"Sachdeva","year":"2009","journal-title":"Am Heart J"},{"issue":"2","key":"R10-5-20210128","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/0021-9150(94)90129-5","article-title":"Role of plasma triglyceride in the regulation of plasma low density lipoprotein (LDL) subfractions: relative contribution of small, dense LDL to coronary heart disease risk.","volume":"106","author":"Griffin","year":"1994","journal-title":"Atherosclerosis"},{"issue":"3","key":"R11-5-20210128","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.pharmthera.2010.01.008","article-title":"Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular risk.","volume":"126","author":"Chapman","year":"2010","journal-title":"Pharmacol Ther"},{"issue":"13","key":"R12-5-20210128","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1056\/NEJMoa064278","article-title":"HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events.","volume":"357","author":"Barter","year":"2007","journal-title":"N Engl J Med"},{"issue":"10","key":"R13-5-20210128","first-page":"806","article-title":"Association of cholesterol with stroke risk varies in stroke subjects and patient subgroups.","volume":"16","author":"Tirschwell","year":"2003","journal-title":"Am J Hypertens"},{"issue":"16","key":"R14-5-20210128","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1097\/MOL.0b013e32800ff750","article-title":"Simultaneous low-density lipoprotein-C lowering and high-density lipoprotein-C elevation for optimum cardiovascular disease prevention with various drug classes, and their combinations: a meta-analysis of 23 randomized lipid trials.","volume":"17","author":"Brown","year":"2006","journal-title":"Curr Opin Lipidol"},{"issue":"4","key":"R15-5-20210128","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1161\/CIRCULATIONAHA.106.637793","article-title":"Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies.","volume":"115","author":"Sarwar","year":"2007","journal-title":"Circulation"},{"issue":"19","key":"R16-5-20210128","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1056\/NEJM199011083231901","article-title":"Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B.","volume":"323","author":"Brown","year":"1990","journal-title":"N Engl J Med"},{"issue":"22","key":"R17-5-20210128","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1056\/NEJMoa011090","article-title":"Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease.","volume":"345","author":"Brown","year":"2001","journal-title":"N Engl J Med"},{"issue":"2","key":"R18-5-20210128","doi-asserted-by":"crossref","first-page":"95","DOI":"10.7326\/0003-4819-142-2-200501180-00008","article-title":"A randomized trial of a strategy for increasing high-density lipoprotein cholesterol levels: effects on progression of coronary heart disease and clinical events.","volume":"142","author":"Whitney","year":"2005","journal-title":"Ann Intern Med"},{"issue":"11","key":"R19-5-20210128","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1016\/j.amjcard.2009.07.035","article-title":"Effects of combination lipid therapy on coronary stenosis progression and clinical cardiovascular events in coronary disease patients with metabolic syndrome: a combined analysis of the Familial Atherosclerosis Treatment Study (FATS), the HDL-Atherosclerosis Treatment Study (HATS), and the Armed Forces Regression Study (AFREGS).","volume":"104","author":"Zhao","year":"2009","journal-title":"Am J Cardiol"},{"issue":"4","key":"R20-5-20210128","doi-asserted-by":"crossref","first-page":"811","DOI":"10.2337\/dc08-9018","article-title":"Lipoprotein management in patients with cardiometabolic risk.","volume":"31","author":"Brunzell","year":"2008","journal-title":"Diabetes Care"},{"issue":"6","key":"R21-5-20210128","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1097\/00041433-200412000-00006","article-title":"Niacin therapy in atherosclerosis.","volume":"15","author":"Meyers","year":"2004","journal-title":"Curr Opin Lipidol"},{"issue":"6","key":"R22-5-20210128","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/S0735-1097(86)80293-5","article-title":"Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin.","volume":"8","author":"Canner","year":"1986","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"R23-5-20210128","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1001\/jama.1975.03240160024021","article-title":"Clofibrate and niacin in coronary heart disease.","volume":"231","year":"1975","journal-title":"JAMA"},{"issue":"1","key":"R24-5-20210128","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1161\/01.CIR.88.1.20","article-title":"Beneficial effects of colestipol-niacin therapy on the common carotid artery: two- and four-year reduction of intima-media thickness measured by ultrasound.","volume":"88","author":"Blankenhorn","year":"1993","journal-title":"Circulation"},{"issue":"10","key":"R25-5-20210128","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1093\/ajhp\/60.10.995","article-title":"Niacin for dyslipidemia: considerations in product selection.","volume":"60","author":"McKenney","year":"2003","journal-title":"Am J Health Syst Pharm"},{"issue":"22","key":"R26-5-20210128","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1056\/NEJMoa0907569","article-title":"Extended-release niacin or ezetimibe and carotid intima-media thickness.","volume":"361","author":"Taylor","year":"2009","journal-title":"N Engl J Med"},{"issue":"11","key":"R27-5-20210128","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1185\/030079906X148508","article-title":"The effect of 24 months of combination statin and extended-release niacin on carotid intima-media thickness: ARBITER 3.","volume":"22","author":"Taylor","year":"2006","journal-title":"Curr Med Res Opin"},{"issue":"23","key":"R28-5-20210128","doi-asserted-by":"crossref","first-page":"3512","DOI":"10.1161\/01.CIR.0000148955.19792.8D","article-title":"Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins.","volume":"110","author":"Taylor","year":"2004","journal-title":"Circulation"},{"issue":"23","key":"R29-5-20210128","doi-asserted-by":"crossref","first-page":"3233","DOI":"10.1001\/jama.1987.03390230069027","article-title":"Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts.","volume":"257","author":"Blankenhorn","year":"1987","journal-title":"JAMA"},{"issue":"suppl F","key":"R30-5-20210128","doi-asserted-by":"crossref","first-page":"F41","DOI":"10.1093\/eurheartj\/sui042","article-title":"Niaspan: creating a new concept for raising HDL-cholesterol.","volume":"7","author":"McGovern","year":"2005","journal-title":"Eur Heart J Suppl"},{"issue":"3","key":"R31-5-20210128","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1177\/107424849600100302","article-title":"Treatment effect of Niaspan, a controlled-release niacin, in patients with hypercholesterolemia: a placebo-controlled trial.","volume":"1","author":"Morgan","year":"1996","journal-title":"J Cardiovasc Pharmacol Ther"},{"issue":"9","key":"R32-5-20210128","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/S0026-0495(98)90284-0","article-title":"Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia.","volume":"47","author":"Knopp","year":"1998","journal-title":"Metabolism"},{"issue":"9","key":"R33-5-20210128","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1016\/S0002-9149(00)00703-7","article-title":"Multiple-dose efficacy and safety of an extended-release form of niacin in the management of hyperlipidemia.","volume":"85","author":"Goldberg","year":"2000","journal-title":"Am J Cardiol"},{"issue":"2","key":"R34-5-20210128","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.atherosclerosis.2009.05.020","article-title":"Management of non-high-density lipoprotein abnormalities.","volume":"207","author":"Rosenson","year":"2009","journal-title":"Atherosclerosis"},{"issue":"10","key":"R36-5-20210128","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1586\/erc.10.116","article-title":"New evidence for nicotinic acid treatments to reduce atherosclerosis.","volume":"8","author":"Monetecucco","year":"2010","journal-title":"Expert Rev Cardiovasc Ther"},{"issue":"4","key":"R37-5-20210128","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.jacl.2007.07.008","article-title":"Revisiting niacin: reviewing the evidence.","volume":"1","author":"Vaccari","year":"2007","journal-title":"J Clin Lipid"},{"issue":"12","key":"R39-5-20210128","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1111\/j.1742-1241.2008.01938.x","article-title":"Lipid-modifying efficacy and tolerability of extended-release niacinlaropiprant in patients with primary hypercholesterolaemia or mixed dyslipidaemia.","volume":"62","author":"Maccubbin","year":"2008","journal-title":"Int J Clin Pract"},{"issue":"3","key":"R40-5-20210128","doi-asserted-by":"crossref","first-page":"310","DOI":"10.3122\/jabfm.19.3.310","article-title":"Hypertriglyceridemia.","volume":"19","author":"Pejic","year":"2006","journal-title":"J Am Board Fam Med"},{"issue":"4","key":"R42-5-20210128","doi-asserted-by":"crossref","first-page":"470","DOI":"10.4065\/83.4.470","article-title":"Effects of niacin on glucose control in patients with dyslipidemia.","volume":"83","author":"Goldberg","year":"2008","journal-title":"Mayo Clin Proc"},{"issue":"3","key":"R44-5-20210128","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1183\/09031936.00127507","article-title":"Health Belief Model predicts adherence to CPAP before experience with CPAP.","volume":"32","author":"Olsen","year":"2008","journal-title":"Eur Respir J"},{"issue":"10","key":"R45-5-20210128","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1111\/j.1365-2036.2005.02497.x","article-title":"Utility of the Health Belief Model in predicting compliance of screening in patients with chronic hepatitis B.","volume":"21","author":"Wai","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"R46-5-20210128","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1177\/109019818801500203","article-title":"Social learning theory and the Health Belief Model.","volume":"15","author":"Rosenstock","year":"1988","journal-title":"Health Educ Q"},{"issue":"3","key":"R47-5-20210128","first-page":"268","article-title":"Compliance with a medical regimen for asthma: a test of the Health Belief Model.","volume":"93","author":"Becker","year":"1978","journal-title":"Public Health Rep"},{"issue":"12","key":"R48-5-20210128","doi-asserted-by":"crossref","first-page":"3400","DOI":"10.1172\/JCI27160","article-title":"Flushing out the role of GPR109A (HM74A) in the clinical efficacy of nicotinic acid.","volume":"115","author":"Pike","year":"2005","journal-title":"J Clin Invest"},{"issue":"6","key":"R50-5-20210128","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1124\/mol.106.030833","article-title":"Nicotinic acid-induced flushing is mediated by activation of epidermal Langerhans cells.","volume":"70","author":"Benyo","year":"2006","journal-title":"Mol Pharmacol"},{"issue":"4","key":"R51-5-20210128","doi-asserted-by":"crossref","first-page":"365","DOI":"10.4065\/mcp.2009.0535","article-title":"A hot topic in dyslipidemia managementhow to beat a flush: optimizing niacin tolerability to promote long-term treatment adherence and coronary disease prevention.","volume":"85","author":"Jacobson","year":"2010","journal-title":"Mayo Clin Proc"},{"issue":"4","key":"R52-5-20210128","doi-asserted-by":"crossref","first-page":"614","DOI":"10.2337\/diacare.20.4.614","article-title":"Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease: a subgroup analysis of the Scandinavian Simvastatin Survival Study (4S).","volume":"20","author":"Pyorala","year":"1997","journal-title":"Diabetes Care"},{"issue":"5","key":"R53-5-20210128","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1161\/01.CIR.101.5.477","article-title":"Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air ForceTexas Coronary Atherosclerosis Prevention Study (AFCAPSTexCAPS).","volume":"101","author":"Gotto","year":"2000","journal-title":"Circulation"},{"issue":"9435","key":"R54-5-20210128","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0140-6736(04)16895-5","article-title":"Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial.","volume":"364","author":"Colhoun","year":"2004","journal-title":"Lancet"},{"issue":"6","key":"R55-5-20210128","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1185\/03007990802083408","article-title":"Dosage, titration, and gaps in treatment with extended release niacin in clinical practice.","volume":"24","author":"Kamal-Bahl","year":"2008","journal-title":"Curr Med Res Opin"},{"issue":"1","key":"R56-5-20210128","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.clinthera.2009.01.011","article-title":"Patients experiences of niacin-induced flushing in clinical practice: a structured telephone interview.","volume":"31","author":"Kamal-Bahl","year":"2009","journal-title":"Clin Ther"},{"issue":"12","key":"R57-5-20210128","doi-asserted-by":"crossref","first-page":"996","DOI":"10.7326\/0003-4819-139-12-200312160-00009","article-title":"Varying cost and free nicotinic acid content in over-the-counter niacin preparations for dyslipidemia.","volume":"139","author":"Meyers","year":"2003","journal-title":"Ann Intern Med"},{"issue":"1","key":"R58-5-20210128","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/j.1520-037X.2006.04736.x","article-title":"Flush-free niacin: dietary supplement may be benefit-free.","volume":"9","author":"Norris","year":"2006","journal-title":"Prev Cardiol"},{"key":"R62-5-20210128","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.cld.2007.06.010","article-title":"Lipid-lowering agents that cause drug-induced hepatotoxicity.","volume":"11","author":"Bhardwaj","year":"2007","journal-title":"Clin Liver Dis"},{"issue":"2","key":"R63-5-20210128","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.jacc.2004.10.031","article-title":"Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials.","volume":"45","author":"Birjmohun","year":"2005","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"R64-5-20210128","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.1038\/sj.jid.5700586","article-title":"Langerhans cells release prostaglandin D2 in response to nicotinic acid.","volume":"126","author":"Maciejewski-Lenoir","year":"2006","journal-title":"J Invest Dermatol"},{"issue":"1","key":"R65-5-20210128","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/clpt.1991.104","article-title":"Tolerance to nicotinic acid flushing.","volume":"50","author":"Stern","year":"1991","journal-title":"Clin Pharmacol Ther"},{"key":"R66-5-20210128","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1111\/j.1742-1241.2009.02099.x","article-title":"The mechanism and mitigation of niacin-induced flushing.","volume":"63","author":"Kamanna","year":"2009","journal-title":"Int J Clin Pract"},{"issue":"6","key":"R67-5-20210128","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1517\/14656566.5.6.1385","article-title":"Extended-release niacin for modifying the lipoprotein profile.","volume":"5","author":"Guyton","year":"2004","journal-title":"Expert Opin Pharmacother"},{"issue":"12A","key":"R68-5-20210128","doi-asserted-by":"crossref","first-page":"35L","DOI":"10.1016\/S0002-9149(00)01468-5","article-title":"The pharmacokinetics and pharmacodynamics of agents proven to raise high-density lipoprotein cholesterol.","volume":"86","author":"Piepho","year":"2000","journal-title":"Am J Cardiol"},{"issue":"3","key":"R69-5-20210128","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/0002-9343(91)90122-E","article-title":"Niacin revisited: clinical observations on an important but underutilized drug.","volume":"91","author":"Henkin","year":"1991","journal-title":"Am J Med"},{"issue":"9","key":"R70-5-20210128","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1001\/jama.1994.03510330050033","article-title":"A comparison of the efficacy and toxic effects of sustained- vs. immediate-release niacin in hypercholesterolemic patients.","volume":"271","author":"McKenney","year":"1994","journal-title":"JAMA"},{"issue":"7","key":"R71-5-20210128","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1001\/archinte.164.7.697","article-title":"New perspectives on the use of niacin in the treatment of lipid disorders.","volume":"164","author":"McKenney","year":"2004","journal-title":"Arch Intern Med"},{"issue":"2","key":"R72-5-20210128","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jacl.2009.02.003","article-title":"Flushing and other dermatologic adverse events associated with extended-release niacin therapy.","volume":"3","author":"Guyton","year":"2009","journal-title":"J Clin Lipidol"},{"issue":"8A","key":"R73-5-20210128","doi-asserted-by":"crossref","first-page":"14B","DOI":"10.1016\/j.amjcard.2008.02.028","article-title":"Niacin use and cutaneous flushing: mechanisms and strategies for prevention.","volume":"101","author":"Davidson","year":"2008","journal-title":"Am J Cardiol"},{"issue":"2","key":"R74-5-20210128","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.jacl.2009.02.009","article-title":"Efficacy and safety of combination therapy with niacin extended-release and simvastatin versus atorvastatin in patients with dyslipidemia: the SUPREME Study.","volume":"3","author":"Insull","year":"2009","journal-title":"J Clin Lipidol"},{"issue":"2","key":"R75-5-20210128","doi-asserted-by":"crossref","first-page":"69","DOI":"10.2165\/00129784-200808020-00001","article-title":"Long-term safety and efficacy of a combination of niacin extended release and simvastatin in patients with dyslipidemia: the OCEANS study.","volume":"8","author":"Karas","year":"2008","journal-title":"Am J Cardiovasc Drugs"},{"issue":"10","key":"R76-5-20210128","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1016\/j.amjcard.2008.02.092","article-title":"Comparison of the safety and efficacy of a combination tablet of niacin extended release and simvastatin vs. simvastatin monotherapy in patients with increased non-HDL cholesterol (from the SEACOAST I study).","volume":"101","author":"Ballantyne","year":"2008","journal-title":"Am J Cardiol"},{"issue":"2","key":"R77-5-20210128","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.jacl.2008.02.004","article-title":"Comparison of the efficacy and safety of a combination tablet of niacin extended-release and simvastatin with simvastatin 80 mg monotherapy: the SEACOAST II (high-dose) study.","volume":"2","author":"Ballantyne","year":"2008","journal-title":"J Clin Lipidol"},{"issue":"16","key":"R78-5-20210128","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1016\/j.jacc.2008.03.003","article-title":"Lipid-altering efficacy and safety of ezetimibesimvastatin coadministered with extended-release niacin in patients with type IIa or type IIb hyperlipidemia.","volume":"51","author":"Guyton","year":"2008","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"R79-5-20210128","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.atherosclerosis.2006.11.037","article-title":"Comparative effects on lipid levels of combination therapy with a statin and extended-release niacin or ezetimibe versus a statin alone (the COMPELL study).","volume":"192","author":"McKenney","year":"2007","journal-title":"Atherosclerosis"},{"issue":"2","key":"R80-5-20210128","doi-asserted-by":"crossref","first-page":"78","DOI":"10.5414\/CPP45078","article-title":"Aspirin reduces cutaneous flushing after administration of an optimized extended-release niacin formulation.","volume":"45","author":"Cefali","year":"2007","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"2","key":"R81-5-20210128","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/BF03256578","article-title":"Acetylsalicylic acid reduces niacin extended-release-induced flushing in patients with dyslipidemia.","volume":"9","author":"Thakkar","year":"2009","journal-title":"Am J Cardiovasc Drugs"},{"issue":"10","key":"R82-5-20210128","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1046\/j.1525-1497.1997.07118.x","article-title":"Effect of two aspirin pretreatment regimens on niacin-induced cutaneous reactions.","volume":"12","author":"Jungnickel","year":"1997","journal-title":"J Gen Intern Med"},{"issue":"7","key":"R83-5-20210128","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1097\/00045391-199506000-00006","article-title":"Low-dose aspirin and ibuprofen reduce the cutaneous reactions following niacin administration.","volume":"2","author":"Dunn","year":"1995","journal-title":"Am J Ther"},{"issue":"2","key":"R84-5-20210128","first-page":"165","article-title":"The effect of aspirin on niacin-induced cutaneous reactions.","volume":"34","author":"Whelan","year":"1992","journal-title":"J Fam Pract"},{"issue":"4","key":"R85-5-20210128","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1097\/CRD.0b013e3181ce1521","article-title":"Use of nonsteroidal anti-inflammatory drugs in patients with cardiovascular disease: a cautionary tale.","volume":"18","author":"Amer","year":"2010","journal-title":"Cardiol Rev"},{"issue":"22","key":"R86-5-20210128","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1056\/NEJMra052717","article-title":"Low-dose aspirin for the prevention of atherothrombosis.","volume":"353","author":"Patrono","year":"2005","journal-title":"N Engl J Med"},{"issue":"suppl 3","key":"R87-5-20210128","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2165\/00019053-200422003-00003","article-title":"Follow-up lipid tests and physician visits are associated with improved adherence to statin therapy.","volume":"22","author":"Benner","year":"2004","journal-title":"Pharmacoeconomics"},{"issue":"12A","key":"R88-5-20210128","doi-asserted-by":"crossref","first-page":"62L","DOI":"10.1016\/S0002-9149(00)01473-9","article-title":"Clinical treatment of dyslipidemia: practice patterns and missed opportunities.","volume":"86","author":"Smith","year":"2000","journal-title":"Am J Cardiol"},{"issue":"12","key":"R89-5-20210128","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1517\/14656566.3.12.1763","article-title":"Niacin extended-releaselovastatin: combination therapy for lipid disorders.","volume":"3","author":"Moon","year":"2002","journal-title":"Expert Opin Pharmacother"},{"issue":"3","key":"R90-5-20210128","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.amjcard.2004.04.024","article-title":"Safety and compliance with once-daily niacin extended-releaselovastatin as initial therapy in the Impact of Medical Subspecialty on Patient Compliance to Treatment (IMPACT) study.","volume":"94","year":"2004","journal-title":"Am J Cardiol"},{"issue":"3","key":"R91-5-20210128","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.jacl.2007.05.003","article-title":"Niacin plus simvastatin reduces coronary stenosis progression among patients with metabolic syndrome despite a modest increase in insulin resistance: a subgroup analysis of the HDL-Atherosclerosis Treatment Study (HATS).","volume":"1","author":"Vittone","year":"2007","journal-title":"J Clin Lipidol"},{"issue":"4","key":"R92-5-20210128","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.amjcard.2005.08.070","article-title":"Benefits of niacin in patients with versus without the metabolic syndrome and healed myocardial infarction (from the Coronary Drug Project).","volume":"97","author":"Canner","year":"2006","journal-title":"Am J Cardiol"},{"issue":"3","key":"R93-5-20210128","doi-asserted-by":"crossref","first-page":"229","DOI":"10.4065\/84.3.229","article-title":"Carotid intima-media thickness and coronary artery calcium score as indications of subclinical atherosclerosis.","volume":"84","author":"Lester","year":"2009","journal-title":"Mayo Clin Proc"},{"key":"R94-5-20210128","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1093\/eurheartj\/ehi441","article-title":"The role of non-invasive imaging in the risk stratification of asymptomatic diabetic subjects.","volume":"27","author":"Anand","year":"2006","journal-title":"Eur Heart J"},{"issue":"1","key":"R95-5-20210128","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3810\/pgm.2010.01.2091","article-title":"Carotid intima-media thickness: knowledge and application to everyday practice.","volume":"122","author":"Cobble","year":"2010","journal-title":"Postgrad Med"},{"issue":"10","key":"R97-5-20210128","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1016\/j.amjcard.2009.07.005","article-title":"Screening for subclinical coronary artery disease measuring carotid intima media thickness.","volume":"104","author":"Nguyen-Thanh","year":"2009","journal-title":"Am J Cardiol"},{"key":"R99-5-20210128","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1161\/01.CIR.0000034670.06526.15","article-title":"ACCAHA 2002 guideline update for exercise testing: summary article: a report of the American College of CardiologyAmerican Heart Association Task Force on Practice Guidelines (Committee to Update the 1997 Exercise Testing Guidelines).","volume":"106","author":"Gibbons","year":"2002","journal-title":"Circulation"},{"issue":"1","key":"R100-5-20210128","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0735-1097(02)02848-6","article-title":"ACCAHA 2002 guideline update for the management of patients with chronic stable angina: summary article.","volume":"41","author":"Gibbons","year":"2003","journal-title":"J Am Coll Cardiol"}],"container-title":["Journal of Cardiovascular Nursing"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/JCN.0b013e31821bf93f","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T01:44:30Z","timestamp":1620956670000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005082-201207000-00005"}},"subtitle":["Contemporary Management of Dyslipidemia to Prevent, Reduce, or Reverse Atherosclerotic Cardiovascular Disease"],"short-title":[],"issued":{"date-parts":[[2012,7]]},"references-count":89,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1097\/jcn.0b013e31821bf93f","relation":{},"ISSN":["0889-4655"],"issn-type":[{"value":"0889-4655","type":"print"}],"subject":[],"published":{"date-parts":[[2012,7]]}}}